NASDAQ:AXDX Accelerate Diagnostics (AXDX) Stock Price, News & Analysis → 8,788% Return Predicted For THIS Crypto (already up 40% in 6 months) (From Paradigm Press) (Ad) Free AXDX Stock Alerts $0.98 +0.03 (+3.16%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$0.95▼$1.0150-Day Range$0.91▼$3.9052-Week Range$0.83▼$11.90Volume63,197 shsAverage Volume137,549 shsMarket Capitalization$14.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Accelerate Diagnostics alerts: Email Address Accelerate Diagnostics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.45% of Float Sold ShortDividend StrengthN/ASustainability-1.62Upright™ Environmental ScoreNews Sentiment0.62Based on 4 Articles This WeekInsider TradingSelling Shares$978 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.94 out of 5 starsMedical Sector591st out of 947 stocksAnalytical Instruments Industry18th out of 29 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Accelerate Diagnostics. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.45% of the float of Accelerate Diagnostics has been sold short.Short Interest Ratio / Days to CoverAccelerate Diagnostics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Accelerate Diagnostics has recently decreased by 13.91%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAccelerate Diagnostics does not currently pay a dividend.Dividend GrowthAccelerate Diagnostics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAccelerate Diagnostics has received a 74.73% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Diagnostic test kits" product. See details.Environmental SustainabilityThe Environmental Impact score for Accelerate Diagnostics is -1.62. Previous Next 2.0 News and Social Media Coverage News SentimentAccelerate Diagnostics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Accelerate Diagnostics this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Accelerate Diagnostics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Accelerate Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $978.00 in company stock.Percentage Held by Insiders33.00% of the stock of Accelerate Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Accelerate Diagnostics is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Accelerate Diagnostics is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsThe only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.Get the stock ticker here >>> About Accelerate Diagnostics Stock (NASDAQ:AXDX)Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. The company was incorporated in 1982 and is headquartered in Tucson, Arizona.Read More AXDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AXDX Stock News HeadlinesMarch 19, 2024 | americanbankingnews.comAccelerate Diagnostics (NASDAQ:AXDX) Receives New Coverage from Analysts at StockNews.comMarch 18, 2024 | finance.yahoo.comAXDX Apr 2024 2.500 callMarch 19, 2024 | Behind the Markets (Ad)The only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.March 16, 2024 | ca.finance.yahoo.comAccelerate Declares Q1 2024 Cash DistributionsMarch 7, 2024 | finance.yahoo.comAccelerate Diagnostics Scheduled Call to Review 2023 Fourth Quarter and Full Year Results.February 18, 2024 | theglobeandmail.comClosing Bell: Accelerate Enhanced CDN Bm Alt Fund ETF flat on Thursday (ATSX)February 17, 2024 | finance.yahoo.comAXDX Mar 2024 2.500 putJanuary 31, 2024 | benzinga.comPeering Into Accelerate Diagnostics's Recent Short InterestMarch 19, 2024 | Weiss Ratings (Ad)The ONE AI sSock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …January 19, 2024 | marketwatch.comAccelerate Diagnostics Shares Plumb New Depths on Stock SaleJanuary 19, 2024 | msn.comWhy Accelerate Diagnostics (AXDX) Stock Is Down 38%January 19, 2024 | msn.comAccelerate Diagnostics prices $15M public offering and private placement, shares fallJanuary 19, 2024 | markets.businessinsider.comAccelerate Diagnostics Prices Public Offering, Private Placement Worth $15 Mln; Stock TanksJanuary 19, 2024 | finance.yahoo.comAccelerate Diagnostics Announces Pricing of Approximately $15 Million Public Offering and Private PlacementJanuary 16, 2024 | msn.comWhy Accelerate Diagnostics (AXDX) Stock Hit A New 52-Week Low TodayJanuary 16, 2024 | markets.businessinsider.comAccelerate Diagnostics Launches Public Offering Of 4.5 Mln Units; Stock Down In Pre-marketJanuary 16, 2024 | finance.yahoo.comAccelerate Diagnostics Announces Launch of Proposed Public OfferingJanuary 8, 2024 | finanznachrichten.deAccelerate Diagnostics, Inc.: Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2023 ResultsJanuary 7, 2024 | markets.businessinsider.comAccelerate Diagnostics Preliminary FY23 Revenue DownJanuary 7, 2024 | finance.yahoo.comAccelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2023 ResultsNovember 22, 2023 | finance.yahoo.comAccelerate Diagnostics (AXDX) Loses -25.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerNovember 11, 2023 | finance.yahoo.comAccelerate Diagnostics, Inc. (NASDAQ:AXDX) Q3 2023 Earnings Call TranscriptNovember 10, 2023 | finanznachrichten.deAccelerate Diagnostics, Inc.: Accelerate Diagnostics Reports Third Quarter 2023 ResultsNovember 10, 2023 | seekingalpha.comAccelerate Diagnostics, Inc. (AXDX) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | finance.yahoo.comAccelerate Diagnostics Reports Third Quarter 2023 ResultsOctober 30, 2023 | finance.yahoo.comAccelerate Diagnostics Scheduled Call to Review 2023 Third Quarter Results.October 3, 2023 | businesswire.comAccelerate Investor Conference Reveals 2023 Keynote Speakers and PanelistsSee More Headlines Receive AXDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Accelerate Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today3/19/2024Next Earnings (Confirmed)3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryN/A Current SymbolNASDAQ:AXDX CUSIPN/A CIK727207 Webacceleratediagnostics.com Phone(520) 365-3100Fax520-269-6580Employees179Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($5.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,490,000.00 Net Margins-472.05% Pretax MarginN/A Return on EquityN/A Return on Assets-137.08% Debt Debt-to-Equity RatioN/A Current Ratio0.86 Quick Ratio0.76 Sales & Book Value Annual Sales$12.75 million Price / Sales1.12 Cash FlowN/A Price / Cash FlowN/A Book Value($2.25) per share Price / Book-0.44Miscellaneous Outstanding Shares14,570,000Free Float9,761,000Market Cap$14.28 million OptionableOptionable Beta0.51 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Jack Phillips (Age 58)CEO, President & Director Comp: $595kMr. Lawrence Michael Mertz (Age 62)Chief Technology Officer Comp: $329.23kMr. David Patience (Age 38)CFO, Principal Financial Officer & Principal Accounting Officer Ms. Maya GowriSenior VP & Head of OperationsLaura PiersonInvestor Relations OfficerMr. John MeduriChief Strategy OfficerMr. Chris ThodeSenior Vice President of US CommercialMs. Rita BoukamelSenior VP & Head of EMEAMore ExecutivesKey CompetitorsTalis BiomedicalNASDAQ:TLISTelesis BioNASDAQ:TBIOPrecipioNASDAQ:PRPOSingular Genomics SystemsNASDAQ:OMICRapid Micro BiosystemsNASDAQ:RPIDView All CompetitorsInsiders & InstitutionsDavid PatienceSold 350 sharesTotal: $336.00 ($0.96/share)Citadel Advisors LLCBought 400 shares on 2/15/2024Ownership: 0.000%Oracle Investment Management Inc.Sold 24,953 shares on 2/14/2024Ownership: 0.766%Jack PhillipsSold 494 sharesTotal: $642.20 ($1.30/share)Wolverine Asset Management LLCBought 100 shares on 2/1/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions AXDX Stock Analysis - Frequently Asked Questions How have AXDX shares performed in 2024? Accelerate Diagnostics' stock was trading at $3.92 at the start of the year. Since then, AXDX shares have decreased by 75.0% and is now trading at $0.98. View the best growth stocks for 2024 here. Are investors shorting Accelerate Diagnostics? Accelerate Diagnostics saw a drop in short interest in February. As of February 29th, there was short interest totaling 299,000 shares, a drop of 13.9% from the February 14th total of 347,300 shares. Based on an average trading volume of 119,900 shares, the short-interest ratio is currently 2.5 days. Currently, 2.5% of the company's shares are sold short. View Accelerate Diagnostics' Short Interest. When is Accelerate Diagnostics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our AXDX earnings forecast. How can I listen to Accelerate Diagnostics' earnings call? Accelerate Diagnostics will be holding an earnings conference call on Thursday, March 28th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "7585609". How were Accelerate Diagnostics' earnings last quarter? Accelerate Diagnostics, Inc. (NASDAQ:AXDX) issued its quarterly earnings results on Tuesday, November, 9th. The medical research company reported ($1.50) EPS for the quarter, topping analysts' consensus estimates of ($3.50) by $2.00. The medical research company had revenue of $3.12 million for the quarter, compared to the consensus estimate of $3.51 million. During the same quarter in the previous year, the firm posted ($3.30) EPS. When did Accelerate Diagnostics' stock split? Accelerate Diagnostics shares reverse split on the morning of Wednesday, July 12th 2023. The 1-10 reverse split was announced on Wednesday, July 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What guidance has Accelerate Diagnostics issued on next quarter's earnings? Accelerate Diagnostics updated its FY 2023 earnings guidance on Monday, January, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $12.1 million-$12.1 million, compared to the consensus revenue estimate of $12.8 million. What other stocks do shareholders of Accelerate Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AT&T (T), AbbVie (ABBV) and Micron Technology (MU). Who are Accelerate Diagnostics' major shareholders? Accelerate Diagnostics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Griffin Asset Management Inc. (8.38%), Oracle Investment Management Inc. (0.77%), Citadel Advisors LLC (0.00%), Wolverine Asset Management LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Patience, Hany Massarany, Jack Phillips, Jack W Schuler, Larry Michael Mertz, Ron Price and Steven Reichling. View institutional ownership trends. How do I buy shares of Accelerate Diagnostics? Shares of AXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AXDX) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceStock-Picking AI Predicts #1 Stock of 2024AltimetrySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Accelerate Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.